Jasper Therapeutics, Inc. Common Stock
JSPRJasper Therapeutics, Inc. (JSPR) is a biotechnology company focused on developing therapies for hematopoietic stem cell transplantation. The company's primary goal is to improve conditioning regimens and expand treatment options for patients with blood disorders, including sickle cell disease, thalassemia, and certain malignancies. Jasper applies its proprietary technologies to create targeted conditioning agents and stem cell therapies to enhance transplant safety and efficacy.
Company News
Jasper Therapeutics reported positive updated clinical data from its BEACON Phase 1b/2a study and open-label extension study of briquilimab for chronic spontaneous urticaria (CSU). The drug demonstrated rapid disease control with 67% of additional BEACON patients achieving complete response at 12 weeks and 75% of CSU participants in the extension...
Law firm investigating potential securities misconduct for Driven Brands and Jasper Therapeutics, alleging false statements about business performance and operational practices.
Law firm reminds investors of class action lawsuits against multiple companies, alleging false or misleading statements about business operations, financial conditions, and prospects.
Rosen Law Firm is notifying investors of a securities class action lawsuit against Therapeutics for allegedly making false or misleading statements about manufacturing controls and product prospects during the period of November 30, 2023 to July 3, 2025.
A class action lawsuit has been filed against Jasper Therapeutics alleging false and misleading statements about manufacturing controls, product prospects, and potential regulatory issues during the period of November 30, 2023 to July 3, 2025.
